Menu
You have to log in or sign up before you can proceed.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.47

€1.47

4.590%
0.065
4.590%
-
 
12.01.26 / Tradegate WKN: A41QA9 / Name: Lir Life Sciences Corp. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Lir Life Sciences Corp.

sharewise wants to provide you with the best news and tools for Lir Life Sciences Corp., so we directly link to the best financial data sources.

News

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

Vancouver, Canada – January 8, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered

LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor

Vancouver, Canada – December 18, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that Dr. Peter Singer, a global

LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies

Vancouver, Canada – December 11, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent

Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies

Vancouver, Canada – December 10, 2025 – Lir Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative